Answers are grounded in this paper and cite their sources.
Early detection of autoimmune psychosis (AP) mediated by anti-neuronal antibodies (Ab) is critical for achieving optimal clinical outcomes. However, evidence remains limited regarding who should be tested, and how to manage Ab positive cases. This large-scale study evaluates proposed clinical criteria for targeted Ab testing in psychiatric services, and describes the clinical course of seropositive patients. Individuals with early psychosis (EP) or persistent psychosis (PP) were prospectively assessed with clinical criteria to determine high- or low-risk status for AP. Blood samples were collected for Ab testing using a fixed cell-based assay. Seropositive individuals were invited for detailed review, including clinical, functional, and cognitive assessments at baseline and 12-month follow-up. Blood samples were collected from 754 individuals ( n = 352 EP, n = 402 PP). Ab were present in 2.3% (17/754), including 3.4% (12/352) of EP and 1.2% (5/402) of PP patients. AP was confirmed in two cerebrospinal fluid (CSF) positive high-risk individuals (Total: 2/754, 0.3%; EP: 1/352, 0.3%; PP: 1/402, 0.2%). Both improved with immunotherapy. Although some low-risk patients were seropositive, none were diagnosed clinically with AP. AP prevalence was low in this cohort. Targeted testing informed by clinical high-risk criteria successfully identified two immunotherapy-responsive AP cases. This approach appears feasible, but requires further validation. People with psychosis and high-risk AP features should be considered for Ab testing in sera and CSF where indicated. Further research is required to embed targeted Ab testing into mental health services.
No takes yet. Share an insight, caveat, or question.
McKeon et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: